SCHEMBL4182276

SCHEMBL4182276

Oc1cccc(-c2cncc(NCc3ccc4c(c3)OCO4)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.62
BRAF P15056 2/20 0.52
CALM1 P0DP23 2/20 0.50
INSR P06213 1/20 0.49
IGF1R P08069 1/20 0.49
SRC P12931 1/20 0.49
CLK4 Q9HAZ1 2/20 0.48
AURKA O14965 1/20 0.47
MAPT P10636 6/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 4/20 0.47
NPSR1 Q6W5P4 3/20 0.46
GFER P55789 1/20 0.46
HSD17B10 Q99714 2/20 0.45
PABPC1 P11940 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160142 0.91 FYN (0.56) FYNBRAFCALM1INSRIGF1R
SCHEMBL4199234 0.87 FYN (0.54) FYNBRAFINSRIGF1RSRC
SCHEMBL4194265 0.84 AURKA (0.56) FYNBRAFAURKAMAPTALDH1A1
SCHEMBL4187618 0.84 BRAF (0.73) FYNBRAFAURKAHSD17B10
SCHEMBL4160677 0.83 FYN (0.73) FYNMAPTKDM4EALDH1A1GAA
SCHEMBL4152969 0.82 MAPT (0.60) FYNBRAFINSRIGF1RSRC
SCHEMBL4192356 0.82 BRAF (0.53) BRAFCLK4AURKAMAPTKDM4E
SCHEMBL4191787 0.80 FYN (0.71) FYNBRAFMAPTKDM4EALDH1A1
SCHEMBL4201126 0.80 FYN (0.71) FYN
SCHEMBL4189096 0.79 FYN (0.64) FYNBRAFMAPTALDH1A1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CALM1 3220/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CALM1 3220/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 FYN 3292/4885BRAF 3225/4885CALM1 3220/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA FYN 173/4885BRAF 1471/4885CALM1 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.